108 indexable Life Sciences companies headquartered in Wallonia, Belgium, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $1.1B across 42 funded companies.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
Volition
Developer of cancer diagnostic tests |
$40M | — | Public | Post IPO Mar 2026 | 104 | 1995 | ↑ Active |
| 2 |
Nyxoah
Provider of a neurostimulation device for obstructive sleep apnea treatments |
$88.7M | — | Public | Post IPO Dec 2025 | 11 | 2009 | ↑ Active |
| 3 |
Bioxodes
Developer of novel peptide therapies for prevention of thrombosis |
$42.6M | — | Series A | Series A Dec 2025 | 7 | 2013 | ↑ Active |
| 4 |
ATB Therapeutics
Developer of mAb based therapy in oncology |
$56.9M | — | Series A | Series A Nov 2024 | 13 | 2017 | ↑ Active |
| 5 |
Novadip
Developer of stem cell-based therapies for bone healing disorders and bone defects |
$77M | — | Series B | Venture Debt Dec 2023 | 39 | 2013 | — |
| 6 |
CryoTherapeutics
Developer of catheter technology for interventional cardiology to treat heart attacks |
$47.5M | — | Series B | Series B Apr 2024 | 1 | 2009 | — |
| 7 |
Univercells
Provider of biomanufacturing technology services for biopharma sector |
$150.6M | — | Series D | Series D Oct 2022 | 88 | 2013 | — |
| 8 |
OncoDNA
Theranostic and genomic company for precision medicine in oncology |
$44.5M | — | Series C | Grant (prize money) Nov 2023 | 37 | 2012 | — |
| 9 |
Amyl Therapeutics
Developer of therapeutics for the treatment of amyloidosis |
$27.7M | — | Series A | Series A Nov 2023 | 4 | 2020 | — |
| 10 |
The Akkermansia Company
Developer of food supplements for human metabolic health issues |
$22.1M | — | Acquired | Venture Debt Dec 2023 | 5 | 2016 | — |
| 11 |
Convert Pharmaceuticals
Developer of small molecule based oncology therapeutics |
$16.7M | — | Series A | Grant (prize money) Jan 2024 | 2 | 2017 | — |
| 12 |
Miracor Medical
Manufacturer of therapeutic medical devices for impaired cardiac function |
$116.5M | — | Series E | Series E Sep 2020 | 16 | 2008 | — |
| 13 |
Imcyse
Developer of a portfolio of pharmaceuticals against multiple diseases |
$57.3M | — | Series B | Series B Feb 2021 | 48 | 2010 | — |
| 14 |
Synergia Medical
Developer of an active implantable neurostimulator and contact-less patient monitoring system |
$14.2M | — | Series B | Series B Jan 2023 | 18 | 2013 | — |
| 15 |
iSTAR Medical
Developer of minimally-invasive glaucoma surgery (MIGS) implant |
$60.8M | — | Series C | Series C Sep 2019 | 28 | 2010 | — |
| 16 |
Bone Therapeutics
Developer of cell therapy products for orthopedics and bone diseases |
$17.9M | — | Public | Post IPO Apr 2022 | 20 | 2006 | — |
| 17 |
Santero Therapeutics
Developer of antibiotics to target resistant pathogens |
$8.6M | — | Series A | Series A Jun 2023 | 3 | 2021 | — |
| 18 |
IBA
Provider of software and hardware solutions for life science and healthcare industry |
$27.3M | — | Public | Grant (prize money) Nov 2021 | 1,800 | 1986 | — |
| 19 |
Cellaion
Developer of therapies for the treatment of chronic liver diseases |
$44.4M | — | Series D | Series D May 2019 | 24 | 2009 | — |
| 20 |
NeuVasQ Biotechnologies
Developer of therapeutics for acute neurological disorders and neurodegenerative diseases |
$23.8M | — | Series A | Series A Jun 2021 | 3 | 2021 | — |
| 21 |
Endo Tools Therapeutics
Developer of an endoscopic catheter for gastroenterologists |
$18.7M | — | Series D | Series D Jan 2021 | 12 | 2008 | — |
| 22 |
Celyad Oncology
Provider of regenerative therapies for the treatment of cancer and cardiovascular diseases |
$9.6M | — | Public | Post IPO Dec 2021 | 32 | 2007 | — |
| 23 |
N-SIDE
Provider of cloud and AI-based analytics for supply chain optimisation |
$11.8M | — | Series B | Series B Mar 2021 | 10 | 2000 | — |
| 24 |
DeuterOncology
Developer of therapeutics for lung cancer |
$6.1M | — | Acquired | Series A Jan 2023 | 4 | 2020 | — |
| 25 |
EsoBiotec
Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production. |
$2.2M | — | Acquired | Series A Dec 2023 | 8 | 2020 | — |
| 26 |
Uteron Pharma
Developing products dedicated to female healthcare. |
$31.1M | — | Deadpooled | Series B Mar 2012 | 13 | 2002 | — |
| 27 |
Epics therapeutics
Developer of small molecules to treat cancer |
$24.7M | — | Series A | Series A Dec 2018 | 30 | 2018 | — |
| 28 |
Syndesi Therapeutics
Developer of small molecule for treating Alzheimer's disease |
$21.1M | — | Acquired | Grant (prize money) Mar 2019 | 1 | 2018 | — |
| 29 |
Oncomfort
Developer of a digital sedation device for managing pain and anxiety |
$11.8M | — | Acquired | Series A Sep 2020 | 4 | 2017 | — |
| 30 |
Diagenode
Developer of portfolio of reagents and kits for epigenetics sequencing solutions |
$8.5M | — | Acquired | Grant (prize money) Sep 2019 | 99 | 2003 | — |
| 31 |
3D-Side
Provider of cloud-based 3D printing solutions to develop medical models and surgical guides |
$2.7M | — | Series C | Series C Jul 2022 | 17 | 2018 | — |
| 32 |
Progenus
Provider of DNA analysis services and diagnostic kits |
$395K | — | Funding Raised | Grant (prize money) Jan 2024 | 14 | 2001 | — |
| 33 |
KiOmed Pharma
Developer of bio-polymer chitosan based products |
$6.7M | — | Series A | Series A Jun 2016 | 20 | 2012 | — |
| 34 |
Apaxen
Developer of small molecules for treating pulmonary diseases |
$3.6M | — | Series A | Series A Sep 2019 | 4 | 2018 | — |
| 35 |
SynAbs
Developer of monoclonal antibody platform against poor immunogenic compounds |
$631.7K | — | Funding Raised | Grant (prize money) Dec 2022 | 8 | 2015 | — |
| 36 |
Delphi Genetics
Provider of research services in molecular biology, protein engineering, and antibody development |
$1.1M | — | Acqui-Hired | Conventional Debt Jun 2016 | 85 | 2001 | — |
| 37 |
Cell Matters
CDMO focused on manufacturing of cell therapy products |
$872K | — | Series A | Series A Jan 2018 | 6 | 2017 | — |
| 38 |
StratiCELL
Integrated solution provider for in vitro testing of skin care and dermatology products |
$440.4K | — | Acquired | Grant (prize money) Oct 2020 | 11 | 2005 | — |
| 39 |
Targetome
Developing ADC (antibody-drug conjugates) for the treatment of cancer such as pancreatic cancer. |
$393.4K | — | Deadpooled | Series B Feb 2016 | — | 2010 | — |
| 40 |
DNAVision
Provider of a wide range of genomic services to the pharmaceutical, food, and biotechnology industries |
$293.6K | — | Funding Raised | Grant (prize money) Feb 2019 | 5 | 2004 | — |
| 41 |
Nuviant Medical
Implantable neurostimulation systems for chronic diseases |
$143K | — | Deadpooled | Grant (prize money) Dec 2015 | 11 | 2014 | — |
| 42 |
DNAlytics
Provider of data-driven personalized medicine from R&D to market access |
$110.1K | — | Funding Raised | Grant (prize money) Sep 2015 | 7 | 2012 | — |
| 43 |
IRE
Provider of radioisotopes for medical and industrial applications, plus related services |
— | — | Funding Raised | Grant (prize money) Feb 2019 | — | 1971 | — |
| 44 |
CorisBio
In vitro diagnostic tests for infectious diseases. |
— | — | Acquired | Grant (prize money) Jan 2018 | 35 | 1996 | — |
| 45 |
TEXERE Biotech
Developer of bone allografts using automated robotic lines |
— | — | Funding Raised | Dec 2016 | 8 | 2016 | — |
| 46 |
PhysIOL
Manufactures innovative intraocular lenses for cataract surgery. |
— | — | Acqui-Hired | PE 2015 | 94 | 1986 | — |
| 47 |
Symbiose Biomaterials
Biologically inspired molecules and polymers for industrial applications |
— | — | Seed | Seed Oct 2014 | 5 | 2013 | — |
| 48 |
HerbalGem
Manufactures a range of natural ingredients based health supplements |
— | — | Acquired | Feb 2011 | 13 | 1986 | — |
| 49 |
Abaxys Therapeutics
Provider of therapeutics for treating neuro-orphan diseases |
— | — | Unfunded | — | — | 2018 | — |
| 50 |
AIP Sutures & Medical Devices
Developer of surgical sutures |
— | — | Unfunded | — | 3 | 1993 | — |
Developer of cancer diagnostic tests. The Nu-Q is used for early cancer diagnostics by detecting nucleosome markers of cancer and early-stage cells in the blood. It has also developed vet cancer screening tests.
Provider of a neurostimulation device for obstructive sleep apnea treatments. The company's product BLAST-OSA (BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnea) is used for treating sleep apnea and calculating ODI (Oxygen Desaturation Index) and AHI (Apnea-Hypopnea Index). Its system consists of an implant and disposable patch, which stimulate the nerves of the tongue to make it move,
Developer of novel peptide therapies for prevention of thrombosis. The Company’s lead programme, Ir-CPI, is being developed for the prevention of thrombosis in a range of applications including cardiopulmonary bypass grafting and percutaneous coronary intervention.
ATB Therapeutics is developing mAb-based therapy in oncology. The company aims to generate a pipeline of assets for hematological and solid cancers. The company is currently entering in preclinical stage.
Developer of stem cell-based therapies for bone healing disorders and bone defects. The company has developed regenerative therapeutics which include NVD-X3 for hard tissue reconstruction and NVD-X2 for soft tissue reconstruction. The m3 platform technology creost is a 3D osteogenic structure from autologous adipose-derived stem cells which reconstruct critical size bone defects without the use of any scaffold.
Developer of catheter technology for interventional cardiology to treat heart attacks. The company focuses on creating a device for use by interventional cardiologists. This technology aims to treat areas of coronary arteries that are prone to causing heart attacks. The goal is to promote arterial repair without the need for a stent.
Univercells technologies have developed instrument systems for the production of antibodies, proteins, and vaccines. The company's proprietary technology includes scale-x bioreactor and nevoline platform. Scale-x bioreactor provides upstream processing of viral products which can help to deliver viral vaccines and gene therapies.
Theranostic and genomic company for precision medicine in oncology. The company's biomarker tests include OncoDEEP for precision medicine, OncoSELECT is a liquid biopsy solution for monitoring and therapeutics, and OncoFOLLOW is to monitor the progression of the tumor. Also has NGS interpretation platform OncoKDM for clinical information and biomarker test platform OncoSHARE.
Developer of therapeutics for the treatment of amyloidosis. The company has a technology platform named ClariTY for developing therapeutic candidates that target multiple misfolded proteins in both progressive peripheral and neurodegenerative rare diseases.
Developer of food supplements for human metabolic health issues. The company's products are formulated with pasteurised Akkermansia that contains chamomile extract, riboflavin and folic acid and to support a healthier gut and control blood glucose levels.
Convert Pharmaceuticals is involved in the development of small molecule-based oncology therapeutics. The company develops hypoxia-activated cytotoxic small molecules. These therapeutics will act complementary to existing therapies in treatment-resistant areas of solid tumors while maintaining a favorable toxicity profile. The lead drug candidate, CP-506, is a hypoxia-activated prodrug.
Miracor Medical is the manufacturer of a therapeutic medical device for patients with impaired cardiac function. It has developed CE-marked PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) impulse system consisting of a driving console and associated catheters for improving outcomes for severe heart attack patients. The PICSO Impulse system increases blood flow to the affected heart tissue and improv
SRIW
Noshaq
Europa
Sambrinvest
SFPI
_1533028695610.png){kind=logo}
Theodorus
Investsud
Vives Fund
Epimede
Invest.BW
Newton Biocapital
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-21.
_1555562288254.png){kind=logo}
_1574398458810.png){kind=logo}
